Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Reckitt Benckiser reaches deal to buy Mead Johnson for $16.6 billion

Published 02/10/2017, 02:39 AM
Updated 02/10/2017, 02:50 AM
© Reuters. Products produced by Reckitt Benckiser; Vanish, Finish, Dettol and Harpic are seen in London

By Martinne Geller

LONDON (Reuters) - Reckitt Benckiser (L:RB) has agreed to buy U.S. infant formula maker Mead Johnson Nutrition (N:MJN) for $16.6 billion, its biggest deal ever and opening up a new market area for the British consumer goods company.

Reckitt, the British maker of Lysol cleaners and Durex condoms, said on Friday it will pay $90 a share for the company, a 30 percent premium to the stock's closing price the day before Reckitt said last week it was in talks to buy Mead Johnson.

Including Mead Johnson's debt, the deal is worth $17.9 billion.

Reckitt said its goal is for the Mead Johnson business to perform at the upper end of estimated category growth of 3 to 5 percent per year in the medium to long term.

It estimated 200 million pounds in annual cost savings by the end of the third full year, and will add to earnings in the first full year. It should add a double-digit percentage rate to earnings by the third year, Reckitt said.

Reckitt also reported fourth-quarter revenue of 2.76 billion pounds, up 1 percent on a like-for-like basis. For the full year, like-for-like revenue rose 3 percent.

Reported earnings for the full year were 256.5p, up 6 percent.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.